Splinter TA - Search Results

1

Teniposide (VM-26) in ovarian cancer: a review.

van der Gaast A, Splinter TA. van der Gaast A, et al. Among authors: splinter ta. Semin Oncol. 1992 Apr;19(2 Suppl 6):95-7. Semin Oncol. 1992. PMID: 1411643 Review.

2

What is the optimal dose and duration of treatment with etoposide? I. Maximum tolerated duration of daily treatment with 50, 75, and 100 mg of oral etoposide.

Splinter TA, van der Gaast A, Kok TC. Splinter TA, et al. Semin Oncol. 1992 Dec;19(6 Suppl 14):1-7. Semin Oncol. 1992. PMID: 1488650

3

What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days.

van der Gaast A, Vlastuin M, Kok TC, Splinter TA. van der Gaast A, et al. Among authors: splinter ta. Semin Oncol. 1992 Dec;19(6 Suppl 14):8-12. Semin Oncol. 1992. PMID: 1488657

4

Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas.

Van Der Gaast A, Verwey J, Prins E, Splinter TA. Van Der Gaast A, et al. Among authors: splinter ta. Cancer. 1990 Feb 1;65(3):422-4. doi: 10.1002/1097-0142(19900201)65:3<422::aid-cncr2820650308>3.0.co;2-y. Cancer. 1990. PMID: 1688727

5

Growing teratoma syndrome successfully treated with lymphoblastoid interferon.

van der Gaast A, Kok TC, Splinter TA. van der Gaast A, et al. Among authors: splinter ta. Eur Urol. 1991;19(3):257-8. doi: 10.1159/000473633. Eur Urol. 1991. PMID: 1855534

6

Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancer.

van der Gaast A, Bontenbal M, Planting AS, Kok TC, Splinter TA. van der Gaast A, et al. Among authors: splinter ta. Ann Oncol. 1994 Nov;5(9):858-60. doi: 10.1093/oxfordjournals.annonc.a059020. Ann Oncol. 1994. PMID: 7661927 Free article. Clinical Trial.

7

Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.

Kok TC, Van der Gaast A, Dees J, Eykenboom WM, Van Overhagen H, Stoter G, Tilanus HW, Splinter TA. Kok TC, et al. Among authors: splinter ta. Br J Cancer. 1996 Sep;74(6):980-4. doi: 10.1038/bjc.1996.469. Br J Cancer. 1996. PMID: 8826870 Free PMC article. Clinical Trial.

8

A phase I dose finding study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancer.

van der Gaast A, Kok TC, Vos R, Kerkhofs L, Splinter TA. van der Gaast A, et al. Among authors: splinter ta. Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-82-S19-85. Semin Oncol. 1997. PMID: 9427273 Clinical Trial.

9

Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer.

van der Gaast A, Kok TC, Kerkhofs L, Siersema PD, Tilanus HW, Splinter TA. van der Gaast A, et al. Among authors: splinter ta. Br J Cancer. 1999 Jun;80(7):1052-7. doi: 10.1038/sj.bjc.6690462. Br J Cancer. 1999. PMID: 10362115 Free PMC article. Clinical Trial.

10

Absolute bioavailability and pharmacokinetics of oral teniposide.

Splinter TA, Holthuis JJ, Kok TC, Post MH. Splinter TA, et al. Semin Oncol. 1992 Apr;19(2 Suppl 6):28-34. Semin Oncol. 1992. PMID: 1411636 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters